Professional
Added to YB: 2024-05-30
Pitch date: 2024-05-23
MRVI [bullish]
Maravai LifeSciences Holdings, Inc.
-66.39%
current return
Author Info
No bio for this author
Company Info
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
Market Cap
$527.9M
Pitch Price
$10.92
Price Target
N/A
Dividend
N/A
EV/EBITDA
-12.75
P/E
-4.32
EV/Sales
4.36
Sector
Life Sciences Tools and Services
Category
growth
RGA Investment Advisors Portfolio Holding: Maravai LifeSciences Holdings, Inc.
MRVI: Maravai LifeSciences - Nucleic acid & biologics safety testing biz at low teens 2026 EBITDA w/ 20%+ growth potential. TriLink subsidiary critical to Pfizer/BioNTech mRNA vax, Cygnus leads quality control for monoclonal antibodies & CAR-T. 70%+ peak margins, 22.6% in 2023 despite COVID rev -66%. Cygnus alone may be worth more than market cap.
Read full article (4 min)